The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand
Research
Bioequivalence Study of Favipiravir 200 mg Tablets in Healthy Thai Volunteers under Fasting Conditions
Author(s): Ekawan Yoosakul, Anas Sunhem, Vipada Khaowroongrueng*, Lalinthip Saeaue, Busarat Karachot, Isariya Techatanawat, Porranee Puranajoti and Praphassorn Surawattanawan
Favipiravir is a broad spectrum antiviral against RNA viruses. It has been considered as a promising treatment
strategy for a pandemic of Coronavirus Disease 2019 (COVID-19). During this urgent need, the Government
Pharmaceutical Organization (GPO), Thailand had developed favipiravir 200 mg tablet formulation (FAVIR®). A
randomized, two-treatment, two-period, two-sequence, single-dose, crossover study was designed to determine the
bioequivalence of two favipiravir 200 mg tablet formulations, FAVIR® and AVIGAN® under fasting conditions.
The plasma-concentration time profiles were used to characterize the rate and extent of absorption of favipiravir
in the test and reference products. The pharmacokinetics parameters were calculated using non-compartmental
model. The analysis of variance did not show any significant differ.. View more»